Ulcerative Colitis Clinical Trial
Official title:
A Phase I, Multicenter, Dose-escalation Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Patients With Active Ulcerative Colitis
This is a Phase I dose-escalation study of MDX-1100. patients with ulcerative colitis will be enrolled into one of four dose cohorts, to receive of MDX-1100 at 0.3, 1.0, 3.0 or 10mg/kg. Three to six patients will be enrolled at each dose level, starting at the lowest dose level, for a maximum of 24 patients to be enrolled into the study. The study is designed to establish the safety and tolerability of single doses of MDX-1100 administered in dose-escalating cohorts to patients with ulcerative colitis. Other study objectives include characterizing a pharmacokinetic profile and pharmacodynamic effects of MDX-1100 and determination of immunogenic response to MDX-1100.
The primary objectives of this study is to establish the safety and tolerability of single
doses of MDX-1100 administered in dose-escalating cohorts to patients with active ulcerative
colitis (UC).
The secondary objectives include:
1. to characterize the pharmacokinetic profile of MDX-1100,
2. to determine the pharmacodynamic effects of MDX-1100 on CXCL10-related surrogate
markers,
3. to obtain preliminary evidence as assessed by the Ulcerative Colitis Disease Activity
Index (DAI),
4. to determine the immunogenic response to MDX-1100, and
5. determine the safety and efficacy of repeat doses in patients who respond to a single
dose of MDX-1100.
This is a Phase I, multicenter, dose-escalation study of MDX-1100 (anti-CXCL10 human
monoclonal antibody) in patients with UC, as defined by standard clinical, endoscopic and
histological criteria and a DAI greater than or equal to 4 and less than or equal to 9.
Three to six patients will be entered into each of 4 cohorts (0.3, 1.0, 3.0 or 10mg/kg).
Starting with the lowest dose cohort (0.3mg/kg), patients will be administered a single dose
of MDX-1100 at Day 1 and will be followed until 70 days from the last dose. Dose escalation
may proceed when the third patient in the cohort has reached Day 29 and if no dose-limiting
toxicities (DLTs) have occurred. Dose escalation may proceed when the sixth patient reaches
Day 29 and <2 DLTs have occurred in the cohort. Dose escalation will continue until the last
cohort is enrolled or the maximum tolerated dose (MTD) is defined.
Patients who respond to the initial dose, as defined by a decrease in the UC disease
activity index (UCDAI) by greater than or equal to 3 points at Day 29 compared to baseline,
will be offered the option of receiving up to 3 additional doses of MDX-1100 at their
originally assigned dose level. Re-dosing will be permitted at the time of disease flare
which is defined as a worsening of the modified UCDAI of greater than or equal to 2 compared
to the prior nadir. In order to obtain PK data, the first re-dose may not be administered
until Day 43 and all subsequent doses may be great than or equal to 28 days apart. A
response in the repeat dosing phase will be defined as a decrease in the mUCDAI of greater
than or equal to 2 as compared to the previous baseline mUCDAI. For the second infusion, the
comparison will use the mUCDAI calculated at Day 29 or subsequent nadir.
The study will terminate approximately 70 days after the last patient has received the last
dose of MDX-1100. It is anticipated that the maximum total time on study for any patient
will be less than 1 year.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |